These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24131485)

  • 41. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma.
    Chi KH; Liu SJ; Li CP; Kuo HP; Wang YS; Chao Y; Hsieh SL
    J Immunother; 2005; 28(2):129-35. PubMed ID: 15725956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multi-disciplinary Concurrent Management of Recurrent Hepatocellular Therapy is Superior to Sequential Therapy.
    Fields TD; Philips P; Scoggins CR; Tatum C; Kelly L; McMasters KM; Martin RCG
    World J Surg; 2017 May; 41(5):1331-1339. PubMed ID: 27905019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma.
    Kuang M; Peng BG; Lu MD; Liang LJ; Huang JF; He Q; Hua YP; Totsuka S; Liu SQ; Leong KW; Ohno T
    Clin Cancer Res; 2004 Mar; 10(5):1574-9. PubMed ID: 15014006
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor vaccine against recurrence of hepatocellular carcinoma.
    Peng BG; Liang LJ; He Q; Kuang M; Lia JM; Lu MD; Huang JF
    World J Gastroenterol; 2005 Feb; 11(5):700-4. PubMed ID: 15655825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A systematic review of publications on charged particle therapy for hepatocellular carcinoma.
    Igaki H; Mizumoto M; Okumura T; Hasegawa K; Kokudo N; Sakurai H
    Int J Clin Oncol; 2018 Jun; 23(3):423-433. PubMed ID: 28871342
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of the outcomes between surgical resection and proton beam therapy for single primary hepatocellular carcinoma.
    Tamura S; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Murayama S; Uesaka K
    Surg Today; 2020 Apr; 50(4):369-378. PubMed ID: 31602531
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Use of autologous tumor vaccine in preventing recurrence of hepatocellular carcinoma].
    Peng BG; Liang LJ; He Q; Zhou F; Lai JM; Lü MD; Huang JF
    Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):772-5. PubMed ID: 16248952
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proton Beam Therapy for Hepatocellular Carcinoma: Multicenter Prospective Registry Study in Japan.
    Mizumoto M; Ogino H; Okumura T; Terashima K; Murakami M; Ogino T; Tamamura H; Akimoto T; Waki T; Katoh N; Araya M; Onoe T; Takagi M; Iwata H; Numajiri H; Okimoto T; Uchinami Y; Maruo K; Shibuya K; Sakurai H
    Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):725-733. PubMed ID: 37778422
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Perioperative blood transfusion has distinct postsurgical oncologic impact on patients with different stage of hepatocellular carcinoma.
    Chen GX; Qi CY; Hu WJ; Wang XH; Hua YP; Kuang M; Peng BG; Li SQ
    BMC Cancer; 2020 May; 20(1):487. PubMed ID: 32471389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proton beam therapy for hepatocellular carcinoma with bile duct invasion.
    Iizumi T; Okumura T; Hasegawa N; Ishige K; Fukuda K; Seo E; Makishima H; Niitsu H; Takahashi M; Sekino Y; Takahashi H; Takizawa D; Oshiro Y; Baba K; Murakami M; Saito T; Numajiri H; Mizumoto M; Nakai K; Sakurai H
    BMC Gastroenterol; 2023 Aug; 23(1):267. PubMed ID: 37537527
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma.
    Kim TH; Park JW; Kim BH; Oh ES; Youn SH; Moon SH; Kim SS; Woo SM; Koh YH; Lee WJ; Kim DY
    Front Oncol; 2020; 10():542. PubMed ID: 32411594
    [No Abstract]   [Full Text] [Related]  

  • 53. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma.
    Kim TH; Park JW; Kim YJ; Kim BH; Woo SM; Moon SH; Kim SS; Koh YH; Lee WJ; Park SJ; Kim JY; Kim DY; Kim CM
    Cancer Res Treat; 2015 Jan; 47(1):34-45. PubMed ID: 25381830
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Stereotactic Body Radiation Therapy Combined With or Without Transcatheter Arterial Chemoembolization for Patients With Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies.
    Kimura T; Aikata H; Doi Y; Imano N; Takeuchi Y; Takahashi I; Nishibuchi I; Katsuta T; Kenjo M; Murakami Y; Awai K; Chayama K; Nagata Y
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818783450. PubMed ID: 29963972
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of Radiation-Induced Liver Disease in Eastern and Western Patients With Hepatocellular Carcinoma Undergoing Proton Beam Therapy.
    Hsieh CE; Venkatesulu BP; Lee CH; Hung SP; Wong PF; Aithala SP; Kim BK; Rao A; Tung-Chieh Chang J; Tsang NM; Wang CC; Lee CC; Lin CC; Tseng JH; Chou WC; Wang YC; Krishnan S; Hong JH
    Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):73-86. PubMed ID: 30797890
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis.
    Mizumoto M; Tokuuye K; Sugahara S; Nakayama H; Fukumitsu N; Ohara K; Abei M; Shoda J; Tohno E; Minami M
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):462-7. PubMed ID: 18243571
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity.
    Oh D; Lim DH; Park HC; Paik SW; Koh KC; Lee JH; Choi MS; Yoo BC; Lim HK; Lee WJ; Rhim H; Shin SW; Park KB
    Am J Clin Oncol; 2010 Aug; 33(4):370-5. PubMed ID: 20142728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Capacity of proton beams in preserving normal liver tissue during proton beam therapy for hepatocellular carcinoma.
    Tsai YL; Takei H; Iizumi T; Okumura T; Sekino Y; Numajiri H; Ishikawa H; Sakae T; Sakurai H
    J Radiat Res; 2021 Jan; 62(1):133-141. PubMed ID: 33392617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recent update of proton beam therapy for hepatocellular carcinoma: A systematic review and meta-analysis.
    Bae SH; Jang WI; Mortensen HR; Weber B; Kim MS; Høyer M
    J Liver Cancer; 2024 Jul; ():. PubMed ID: 38961722
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Challenges in cancer vaccine development for hepatocellular carcinoma.
    Buonaguro L; Petrizzo A; Tagliamonte M; Tornesello ML; Buonaguro FM
    J Hepatol; 2013 Oct; 59(4):897-903. PubMed ID: 23714157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.